SEARCH:   Advanced

Blood, 1 July 2007, Vol. 110, No. 1, pp. 151-160. Prepublished online as a Blood First Edition Paper on March 22, 2007; DOI 10.1182/blood-2006-10-047092. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2006-10-047092v1 110/1/151    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nagano, M. Articles by Ohneda, O. Search for Related Content PubMed PubMed Citation Articles by Nagano, M. Articles by Ohneda, O. Related Collections Hematopoiesis and Stem Cells Hemostasis, Thrombosis, and Vascular Biology Stem Cells in Hematology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood Masumi Nagano1, Toshiharu Yamashita1, Hiromi Hamada2, Kinuko Ohneda3, Ken-ichi Kimura1, Tomoki Nakagawa1, Masabumi Shibuya4, Hiroyuki Yoshikawa2, and Osamu Ohneda1 Graduate School of Comprehensive Human Sciences1 Department of Regenerative Medicine, 2 Department of Obstetrics and Gynecology, University of Tsukuba, Japan; 3 Laboratory of Molecular Pathophysiology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Japan; 4 Division of Genetics, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan Umbilical cord blood (UCB) has been used as a potential source of various kinds of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells (EPCs), for a variety of cell therapies. Recently, EPCs were introduced for restoring vascularization in ischemic tissues. An appropriate procedure for isolating EPCs from UCB is a key issue for improving therapeutic efficacy and eliminating the unexpected expansion of nonessential cells. Here we report a novel method for isolating EPCs from UCB by a combination of negative immunoselection and cell culture techniques. In addition, we divided EPCs into 2 subpopulations according to the aldehyde dehydrogenase (ALDH) activity. We found that EPCs with low ALDH activity (Alde-Low) possess a greater ability to proliferate and migrate compared to those with high ALDH activity (Alde-High). Moreover, hypoxia-inducible factor proteins are up-regulated and VEGF, CXCR4, and GLUT-1 mRNAs are increased in Alde-Low EPCs under hypoxic conditions, while the response was not significant in Alde-High EPCs. In fact, the introduction of Alde-Low EPCs significantly reduced tissue damage in ischemia in a mouse flap model. Thus, the introduction of Alde-Low EPCs may be a potential strategy for inducing rapid neovascularization and subsequent regeneration of ischemic tissues. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Yamashita, O. Ohneda, A. Sakiyama, F. Iwata, K. Ohneda, and Y. Fujii-Kuriyama The microenvironment for erythropoiesis is regulated by HIF-2{alpha} through VCAM-1 in endothelial cells Blood, August 15, 2008; 112(4): 1482 - 1492. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020